AU2002224417A1 - Methods for treating il-18 mediated disorders - Google Patents
Methods for treating il-18 mediated disordersInfo
- Publication number
- AU2002224417A1 AU2002224417A1 AU2002224417A AU2441702A AU2002224417A1 AU 2002224417 A1 AU2002224417 A1 AU 2002224417A1 AU 2002224417 A AU2002224417 A AU 2002224417A AU 2441702 A AU2441702 A AU 2441702A AU 2002224417 A1 AU2002224417 A1 AU 2002224417A1
- Authority
- AU
- Australia
- Prior art keywords
- treating
- methods
- mediated disorders
- mediated
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24140800P | 2000-10-18 | 2000-10-18 | |
US60/241,408 | 2000-10-18 | ||
PCT/US2001/032460 WO2002032374A2 (en) | 2000-10-18 | 2001-10-17 | Methods for treating il-18 mediated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002224417A1 true AU2002224417A1 (en) | 2002-04-29 |
Family
ID=22910578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002224417A Abandoned AU2002224417A1 (en) | 2000-10-18 | 2001-10-17 | Methods for treating il-18 mediated disorders |
Country Status (3)
Country | Link |
---|---|
US (3) | US20020098185A1 (en) |
AU (1) | AU2002224417A1 (en) |
WO (1) | WO2002032374A2 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
WO2001035974A2 (en) * | 1999-11-15 | 2001-05-25 | Pharma Mar S.A. | Aplidine treatment of cancers |
KR101111103B1 (en) * | 2000-02-10 | 2012-02-13 | 아보트 러보러터리즈 | Antibodies that bind human interleukin-18 and methods of making and using |
CN1322897C (en) * | 2000-02-21 | 2007-06-27 | 应用研究系统Ars股份公司 | Use of IL-18 inhibitors |
US6899869B2 (en) * | 2000-04-25 | 2005-05-31 | Tomoaki Hoshino | Method of preparing an animal model for interstitial pneumonia |
AU2002211744B8 (en) | 2000-10-11 | 2008-03-20 | Viron Therapeutics, Inc. | Nucleic acid molecules and polypeptides for immune modulation |
US7507766B2 (en) * | 2000-10-12 | 2009-03-24 | Pharma Mar, S.A. | Treatment of cancers |
US7718368B2 (en) | 2000-12-04 | 2010-05-18 | Viron Therapeutics Inc. | Immunomodulatory protein and useful embodiments thereof |
ME00549B (en) * | 2001-01-29 | 2011-10-10 | Serono Lab | Use of il-18 inhibitors for the treatment and/or prevention of heart disease |
ES2334773T3 (en) * | 2001-05-16 | 2010-03-16 | Yeda Research And Development Co. Ltd. | USE OF IL-18 INHIBITORS FOR THE TREATMENT OR PREVENTION OF SEPSIS. |
CA2445664C (en) * | 2001-05-25 | 2012-03-06 | Ares Trading S.A. | Use of il-18 inhibitors for treating or preventing cns injuries |
UA78516C2 (en) * | 2001-08-10 | 2007-04-10 | Applied Research Systems | Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity |
CA2462642A1 (en) * | 2001-10-19 | 2003-04-24 | Pharma Mar, S.A. | Use of aplidine for the treatment of pancreatic cancer |
PL207303B1 (en) * | 2002-03-22 | 2010-11-30 | Inst Nat Sante Rech Med | Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases |
CA2500577C (en) | 2002-10-08 | 2013-12-17 | Charles A. Dinarello | The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine |
US7790762B2 (en) * | 2002-10-31 | 2010-09-07 | National Jewish Health | Compounds and methods for thiol-containing compound efflux and cancer treatment |
US20040087527A1 (en) * | 2002-10-31 | 2004-05-06 | Day Brian J. | Methods for treatment of thiol-containing compound deficient conditions |
US20080221029A1 (en) * | 2002-10-31 | 2008-09-11 | Regents Of The University Of Colorado | Methods for treatment of thiol-containing compound deficient conditions |
US7445779B2 (en) * | 2002-12-31 | 2008-11-04 | Schering Corporation | Methods of modulating IFNy production |
US20040191172A1 (en) * | 2003-01-30 | 2004-09-30 | Tomoaki Hoshino | Preventive or therapeutic agents for dermatitis or alopecia, evaluation method of the agents, and transgenic mouse |
EP1603584B1 (en) * | 2003-03-12 | 2008-08-27 | Dana-Farber Cancer Institute, Inc. | Aplidine for multiple myeloma treatment |
US20080076708A1 (en) * | 2003-05-13 | 2008-03-27 | Valter Altarocca | Active Variants of the Il-18 Binding Protein and Medical Uses Thereof |
US7968684B2 (en) * | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
IL159670A0 (en) * | 2003-12-31 | 2004-06-01 | Yeda Res & Dev | Use of il-18 binding protein in inflammations |
EP1736168A4 (en) * | 2004-03-11 | 2008-07-09 | Redox Bioscience Inc | Protease inhibitor and preventives or remedies for diseases |
US7557084B2 (en) | 2004-03-31 | 2009-07-07 | Regeneron Pharmaceuticals, Inc. | IL-18 specific polypeptides and therapeutic uses thereof |
JP5595632B2 (en) * | 2004-07-16 | 2014-09-24 | 敦生 関山 | IL-18 receptor antagonist and pharmaceutical composition comprising said antagonist |
AU2011226823B2 (en) * | 2004-07-16 | 2012-09-20 | Atsuo Sekiyama | IL-18 receptor antagonist and pharmaceutical composition containing the antagonist |
ME02746B (en) | 2004-10-08 | 2018-01-20 | Forward Pharma As | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
JP5048658B2 (en) | 2005-06-03 | 2012-10-17 | メルク セローノ ソシエテ アノニム | Use of IL-18BP isoforms for the treatment and / or prevention of neuroinflammatory diseases |
CA2635472A1 (en) * | 2006-02-22 | 2007-08-30 | University Of Zurich | Soluble receptors and methods for treating autoimmune or demyelinating diseases |
CA2635445A1 (en) * | 2006-02-22 | 2007-08-30 | University Of Zurich | Methods for treating autoimmune or demyelinating diseases |
US8133978B2 (en) | 2006-05-25 | 2012-03-13 | Glaxo Group Limited | Humanised anti-interleukin-18 antibody |
SE532249C2 (en) * | 2006-11-13 | 2009-11-24 | Theravac Pharmaceuticals Ab | New formulations of IL-18 for the treatment of various inflammatory diseases by vaccination |
WO2008150431A1 (en) * | 2007-05-29 | 2008-12-11 | Yale University | Il- 18 and protein kinase r inhibition for the treatment of copd |
CL2008002153A1 (en) | 2007-07-24 | 2009-06-05 | Amgen Inc | Isolated antibody or antigen-binding fragment thereof that binds to the yl-18 (yl-18r) receptor; encoding nucleic acid molecule; host cell comprising it; pharmaceutical composition; medical use to treat or prevent a condition associated with il-18r; In vitro method to inhibit the binding of yl-18 to yl-18r. |
US20110150871A1 (en) * | 2008-08-18 | 2011-06-23 | Glaxo Group Limited | Treatment of an autoimmune disease using il-18 antagonists |
US20120308564A1 (en) * | 2010-02-09 | 2012-12-06 | Andrew Ian Bayliffe | Treatment of a metabolic disorder |
BR112013008501A2 (en) * | 2010-10-08 | 2016-08-16 | Novartis Ag | Methods for treating psoriasis using il-17 anatgonists |
JOP20200308A1 (en) | 2012-09-07 | 2017-06-16 | Novartis Ag | IL-18 binding molecules |
SG11201601717VA (en) | 2013-09-05 | 2016-04-28 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in inflammatory diseases |
RU2755691C2 (en) | 2015-03-05 | 2021-09-20 | Аб2 Био Са | Il-18-binding protein (il-18bp) and antibodies in inflammatory diseases |
US11091795B2 (en) | 2016-07-11 | 2021-08-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for diagnosing and treating arrhythmias |
WO2019213686A1 (en) * | 2018-05-10 | 2019-11-14 | The Council Of The Queensland Institute Of Medical Research | Therapeutic compositions and uses therefor |
WO2020163715A1 (en) * | 2019-02-08 | 2020-08-13 | Cedars-Sinai Medical Center | Methods, systems, and kits for treating inflammatory disease targeting il18r1 |
CA3191161A1 (en) | 2020-08-14 | 2022-02-17 | Kite Pharma, Inc | Improving immune cell function |
WO2023286694A1 (en) * | 2021-07-13 | 2023-01-19 | 国立大学法人東海国立大学機構 | Medicinal composition for treating inflammatory bowel disease |
WO2023220560A1 (en) * | 2022-05-09 | 2023-11-16 | Minerva Biotechnologies Corporation | Chimeric antigen receptor and il-18 receptor compositions and methods of use therein |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
DK0628639T3 (en) * | 1991-04-25 | 2000-01-24 | Chugai Pharmaceutical Co Ltd | Reconstituted human antibody to human interleukin-6 receptor |
EP0692536B1 (en) * | 1994-07-14 | 2000-11-22 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | IFN-Y production inducing protein and monoclonal antibody of the same |
NZ322197A (en) * | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
US5776731A (en) * | 1996-02-21 | 1998-07-07 | Immunex Corporation | DNA encoding type-I interleukin-I receptor-like protein designated 2F1 |
EP0816499A3 (en) * | 1996-06-27 | 1999-10-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma |
US7141393B2 (en) * | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
US6087116A (en) * | 1997-03-12 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18 (IL-18) receptor polypeptides and their uses |
JP2001522357A (en) * | 1997-04-24 | 2001-11-13 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Substituted imidazoles useful for treating inflammatory diseases |
AR022952A1 (en) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | MONOCLONAL ANTIBODY OF ROEDOR SPECIFICALLY NEUTRALIZING FOR HUMAN INTERLEUQUINE-18, A FAB NEUTRALIZING FRAGMENT OR FRAGMENT F (AB ') 2, A COMPLEMENTARITY REGION OF IMMONOGLOBULIN LIGHT CHAIN (CDR), WHICH MAKES IT COMPRESSED , THE |
US6497870B1 (en) * | 2000-05-22 | 2002-12-24 | Hyseq, Inc. | Therapeutic uses of il-1 receptor antagonist |
-
2001
- 2001-10-17 AU AU2002224417A patent/AU2002224417A1/en not_active Abandoned
- 2001-10-17 WO PCT/US2001/032460 patent/WO2002032374A2/en active Application Filing
-
2002
- 2002-01-18 US US09/981,421 patent/US20020098185A1/en not_active Abandoned
-
2007
- 2007-02-28 US US11/712,654 patent/US20080213257A1/en not_active Abandoned
-
2009
- 2009-08-03 US US12/534,755 patent/US20090297517A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090297517A1 (en) | 2009-12-03 |
WO2002032374A2 (en) | 2002-04-25 |
US20080213257A1 (en) | 2008-09-04 |
WO2002032374A3 (en) | 2002-09-19 |
US20020098185A1 (en) | 2002-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002224417A1 (en) | Methods for treating il-18 mediated disorders | |
AU2001285159A1 (en) | Methods for treating endocrine disorders | |
AU7085100A (en) | Method for treating otic disorders | |
AU2001231223A1 (en) | Therapeutic method for reducing angiogenesis | |
AU2001269799A1 (en) | Methods for treating various eye disorders | |
AU2001288271A1 (en) | Methods for treating inflammatory diseases | |
AU2002215125A1 (en) | Well treatment method | |
AU2001227966A1 (en) | Methods for treating tumors | |
AU2001252605A1 (en) | Laser treatment apparatus | |
AU8298801A (en) | Methods for treating atopic disorders | |
AU2002240401A1 (en) | Methods and apparatus for treating hemorrhoids and similar ailments | |
AU2001267212A1 (en) | Ozonation process | |
AU2002225930A1 (en) | Methods for treating phosphatide-containing mixtures | |
AU2001237939A1 (en) | Methods for treating glaucoma | |
AU2001275209A1 (en) | Power steering apparatus | |
AU2002308642A1 (en) | Methods for treating cancer | |
AU2002214487A1 (en) | Method for inducing apoptiosis | |
AU2002326991A1 (en) | Methods for treating multiple sclerosis | |
AU2001295036A1 (en) | Apparatus for performing microcurrentelectrotherapy | |
AU2001290122A1 (en) | Audio apparatus | |
AU2002225327A1 (en) | Apparatus for aesthetic treatment | |
AU2002258798A1 (en) | Methods for the treatment of hepatic disorders | |
AU2001261324A1 (en) | Psoriasis treatment | |
AU2002356482A1 (en) | Strewing apparatus | |
AUPR964901A0 (en) | Waste treatment apparatus |